Visiopharm A/S acquires LRI Imaging AB to become a leader in Diagnostic Digital Pathology

Share Article

Visiopharm A/S today announces its acquisition of LRI Imaging AB.

News Image
We are convinced that digital pathology will lead to improvements in the patient care and help us cope with the growing case load and complexity all diagnostic labs are experiencing. This will benefit both patients individually and society in general

With more than 10 years of experience in the field, many successful installations in routine diagnostic pathology labs, LRI Imaging AB is the leading diagnostic digital pathology provider in Sweden. Today, Visiopharm A/S has implemented diagnostic digital pathology at a national scale in Denmark, as well as several other systems in Europe.With a staff of almost 50 digital pathology experts, Visiopharm A/S and LRI Imaging AB are jointly becoming a highly specialized European leader in Diagnostic Digital Pathology solutions.

“We are now seeing diagnostic digital pathology take off; and not just in Scandinavia, but in large parts of Europe. An important experience from the last 10 years is that going digital is a major undertaking for the pathology lab. We are excited about this merger, which allow us to offer our joint experience and expertise in helping diagnostic pathology labs going digital - one cost-efficient and risk-free step at a time. Our joint expertise gives us a depth of practical expertise in all critical aspects of digital pathology, allowing us to become a true partner in helping pathology labs both implement and take full advantage of this type of technology”, says Michael Grunkin CEO of Visiopharm

Rickard Lindelöf, CEO of LRI Imaging / Visiopharm AB, adds: “For almost a decade we have provided diagnostic digital pathology solutions to Swedish pathology labs. We have done that by integrating best-of-breed solution components. The technology developed by Visiopharm allow us to finally realize the full potential of diagnostic digital pathology: Integrating image analysis in LIS-driven workflows, which is giving pathologists access to validated technology that will improve both data quality and productivity while reducing costs and turnaround times”.

“We have been running several large clinical studies using this technology, of which some have already been published. That has allowed us to see firsthand to what extent image analysis, if used in the right way, can give significant improvements in diagnostic data quality. We believe this will have a great impact on patient safety. And we are excited to see such technology integrated in an open end-to-end digital pathology solution. We are convinced that digital pathology will lead to improvements in the patient care and help us cope with the growing case load and complexity all diagnostic labs are experiencing. This will benefit both patients individually and society in general,” says Johan Hartmann, Professor at Karolinska University Hospital.

Visiopharm offers a truly open and agnostic end-to-end diagnostic pathology solution with best-of-breed components spanning:

1. Best in class slide scanning technology
2. Viewing technology and pathologist cockpit which is setting new standards regarding speed, simplicity, and design. Open to all commercially available slide formats, and enabled for advanced image analysis
3. Support for a range of image management systems, including pathology PACS and VNA.
4. Patent protected, documented and CE-IVD marked computer aided diagnosis (CAD) software scientifically validated improvements to data quality and productivity in a pathology lab. IVD-APPs are validated for all major reagent providers
5. Fully integrated with local LIS systems , providing LIS-driven workflow solutions. Custom integration to other LIS solutions provided as part of the package.
6. A team of experts with deep practical experience in deploying, integrating and supporting end-to-end digital pathology solutions in the daily routine of a pathology lab
7. Change management services and teams allowing our clients to reap the full benefit of their investment

About Visiopharm
Visiopharm is a leading provider of quantitative image analysis software and end-to-end Digital Pathology solutions for Hospitals, biopharmaceutical companies and research institutions around the world. Recently, Visiopharm has expanded to include ONCOTOPIX® Diagnostics a robust solution for cancer diagnostics with CE-IVD algorithms for the breast panel, integrated LIS driven workflow, and VirtualDoubleStaining™. Visiopharm’s software is featured in over 900 scientific publications, and is compatible with leading slide scanner manufacturers, data management software, and staining providers.

Visiopharm, a privately owned company, is an international business with over 600 licenses placed, with countless users, in more than 30 countries. A growing network of authorized distributors and integration partners support the growth of Visiopharm solutions on several continents including North America, Europe and Asia.

About LRI Imaging AB
LRI, a privately owned company, with installations in more than 20 laboratories and nearly 50 scanners placed in Sweden and Norway, is a leading provider of digital slide scanning and end-to-end Digital Pathology solutions including macro cameras for hospitals. With more than 30 years of experience in the pathology field LRI has a broad knowledge in laboratory workflow and has been able to successfully expanded its business in a rapidly growing market due to an always open mind to customers’ need and a great portfolio of solutions.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Helle Fisker
@Visiopharm
Follow >
Visiopharm
since: 12/2011
Like >
Visit website